A Phase 3 Open-label Randomized Study of Nivolumab Combined with Ipilimumab or with Standard of Care Chemotherapy versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Urothelial Cancer
  • Age: Between 18 years - 80 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients have evidence of metastatic or surgically unresectable transitional cell carcinoma (TCC) of the urothelium involving the renal pelvis, ureter, bladder or urethra.

You may not be eligible for this study if the following are true:

  • 1) The Patients have diseases that are suitable for local therapies administrated with curative intent. 2) Patient with active brain metastases or leptomeningeal metastases. 3) Patients who have prior malignancy active within the previous 3 years except for locally curable cancer that have been apparently cured.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.